drugset / Trial / NCT01471054

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054 ↗

Phase 2 Terminated 6 enrolled Arman Mashayekhi Allergan · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema after plaque radiotherapy of uveal melanoma.

Timeline

Start
2014-04
Primary completion
2015-07
Completion
2015-07

Outcome

Outcome not reported

Stopped (Enrollment): “Could not enroll enough patients.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody — Intravitreal
Subject Dexamethasone Small molecule 0.7 mg Intravitreal